Document detail
ID

doi:10.1186/s12864-024-10538-1...

Author
Pottinger, Tess D. Motelow, Joshua E. Povysil, Gundula Moreno, Cristiane A. Martins Ren, Zhong Phatnani, Hemali Aitman, Timothy J. Santoyo-Lopez, Javier Mitsumoto, Hiroshi Goldstein, David B. Harms, Matthew B. The New York Genome Center ALS Sequencing Consortium Scottish Genomes Partnership ALS COSMOS Study Group PLS COSMOS Study Group GTAC Investigators
Langue
en
Editor

BioMed Central

Category

Life Sciences

Year

2024

listing date

7/3/2024

Keywords
amyotrophic lateral sclerosis als peripheral lateral sclerosis pls burden testing rare-variant analyses based antxr2 disease model variant collapsing significant gene pls analyses
Metrics

Abstract

Background Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting over 300,000 people worldwide.

It is characterized by the progressive decline of the nervous system that leads to the weakening of muscles which impacts physical function.

Approximately, 15% of individuals diagnosed with ALS have a known genetic variant that contributes to their disease.

As therapies that slow or prevent symptoms continue to develop, such as antisense oligonucleotides, it is important to discover novel genes that could be targets for treatment.

Additionally, as cohorts continue to grow, performing analyses in ALS subtypes, such as primary lateral sclerosis (PLS), becomes possible due to an increase in power.

These analyses could highlight novel pathways in disease manifestation.

Methods Building on our previous discoveries using rare variant association analyses, we conducted rare variant burden testing on a substantially larger multi-ethnic cohort of 6,970 ALS patients, 166 PLS patients, and 22,524 controls.

We used intolerant domain percentiles based on sub-region Residual Variation Intolerance Score (subRVIS) that have been described previously in conjunction with gene based collapsing approaches to conduct burden testing to identify genes that associate with ALS and PLS.

Results A gene based collapsing model showed significant associations with SOD1 , TARDBP , and TBK1 (OR = 19.18, p  = 3.67 × 10^–39; OR = 4.73, p  = 2 × 10^–10; OR = 2.3, p  = 7.49 × 10^–9, respectively).

These genes have been previously associated with ALS.

Additionally, a significant novel control enriched gene, ALKBH3 ( p  = 4.88 × 10^–7), was protective for ALS in this model.

An intolerant domain-based collapsing model showed a significant improvement in identifying regions in TARDBP that associated with ALS (OR = 10.08, p  = 3.62 × 10^–16).

Our PLS protein truncating variant collapsing analysis demonstrated significant case enrichment in ANTXR2 ( p  = 8.38 × 10^–6).

Conclusions In a large multi-ethnic cohort of 6,970 ALS patients, collapsing analyses validated known ALS genes and identified a novel potentially protective gene, ALKBH3 .

A first-ever analysis in 166 patients with PLS found a candidate association with loss-of-function mutations in ANTXR2 .

Pottinger, Tess D.,Motelow, Joshua E.,Povysil, Gundula,Moreno, Cristiane A. Martins,Ren, Zhong,Phatnani, Hemali,Aitman, Timothy J.,Santoyo-Lopez, Javier,Mitsumoto, Hiroshi,Goldstein, David B.,Harms, Matthew B.,The New York Genome Center ALS Sequencing Consortium,Scottish Genomes Partnership,ALS COSMOS Study Group,PLS COSMOS Study Group,GTAC Investigators, 2024, Rare variant analyses validate known ALS genes in a multi-ethnic population and identifies ANTXR2 as a candidate in PLS, BioMed Central

Document

Open

Share

Source

Articles recommended by ES/IODE AI

Diabetes and obesity: the role of stress in the development of cancer
stress diabetes mellitus obesity cancer non-communicable chronic disease stress diabetes obesity patients cause cancer